HYBENX
Commercial- Indications
- Oral tissue injuries
Company intelligence / Profile preview
EPIEN Medical develops nonbiologic therapeutic products based on a proprietary chemical desiccation process to rapidly debride biofilm and bacteria from impaired tissue. Their lead commercialized dental products—HYBENX and ERADX—are FDA-cleared as adjuncts to periodontal debridement. Clinical data show their technology can reduce or eliminate the need for antibiotics in topical infectious wound care. The company’s pipeline includes REVITY, a candidate targeting chronic wounds currently advancing through clinical development.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EPIEN Medical.